Delivery Order 75N91019D00027-75N91021F00001
Award Date
2/26/21
Potential Completion Date
2/25/22
Potential Value
$1.3M
Federal Agency
National Cancer Institute
Awardee
Kindred Biosciences, Inc.
Ultimate Awardee
Not listed
PSC Category
R499 - Support- Professional: Other
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Burlingame, CA 94010, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract was awarded by the National Cancer Institute (NCI), a civilian agency under the Department of Health and Human Services, to the University of Oklahoma (OU). The $1,891,140.00 firm fixed price delivery order is for a program titled "PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" and is focused on developing a novel mRNA vaccine to prevent triple negative breast cancer. The contract has an ultimate...
This is a $547,860 delivery order contract awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to The Institute for Cancer Research, a non-profit research organization. The contract is part of the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle, which supports the PREVENT Cancer Preclinical Drug Development Program. Under this 5-year IDIQ, The Institute for Cancer Research provides preclinical efficacy...
This federal contract award was issued by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit organization and subsidiary of Temple University. The $1,570,991.00 task order is part of the PREVENT Preclinical Drug Development Program, which focuses on preclinical efficacy and intermediate endpoint biomarker testing for cancer prevention drug candidates. The task order is for a project titled...
This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $1,259,678.78 contract is to provide support for the preclinical development of an endoxifen gel, including pharmacology, toxicology, and safety studies to support an Investigational New Drug (IND) application. This contract is part of the NCI's PREVENT...
This federal contract award is for a two-year base period with a potential one-year extension to support preclinical studies for an LFA-9 (MPGES-1/5-LOX inhibitor) drug candidate. The contract was awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization and division of the Illinois Institute of Technology (IIT). The $1,984,772.00 firm fixed-price...
This is a delivery order contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit research organization and subsidiary of Temple University. The $988,252 firm fixed price contract is for research and development services in the area of biomedical basic research, specifically preclinical efficacy and biomarker analysis to support the NCI's PREVENT Cancer Preclinical Drug Development Program....
This is a delivery order issued under the PREVENT Preclinical Drug Development Program contract, a $150 million multiple-award indefinite delivery/indefinite quantity (IDIQ) contract with the National Cancer Institute (NCI). The award to the IIT Research Institute (IITRI), a non-profit division of the Illinois Institute of Technology, is for the preclinical development of an RNA vaccine for immunoprevention of prostate cancer. The total value of this specific task order is $1,742,384.00. IITRI...
This firm fixed price delivery order contract was awarded to The Institute for Cancer Research, a non-profit subsidiary of Temple University, by the National Cancer Institute (NCI). The contract is a task order under the larger "PREVENT Preclinical Drug Development Program (PREVENT)" indefinite delivery contract, which aims to provide preclinical efficacy and biomarker analysis services to support the evaluation of candidate chemopreventive and immunopreventive regimens. This...
This federal contract award with award ID HHSN261201500024I|HHSN26100003 was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS). The $321,110.80 award was made on September 15, 2016 to the IIT Research Institute (IITRI), a non-profit research organization and division of the Illinois Institute of Technology (IIT). The contract is for the "PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS" under the NCI's PREVENT...
The Institute For Cancer Research, a non-profit subsidiary of Temple University, has been awarded a $884,185.34 firm fixed price delivery order against the National Cancer Institute's PREVENT Cancer Program multiple award indefinite delivery contract vehicle. This delivery order focuses on continued evaluation of candidate chemopreventive and immunopreventive regimens in support of the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS through January...